IC
DNTH icon

Ikarian Capital’s Dianthus Therapeutics DNTH Stock Holding History

Ikarian Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-346,001
Closed -$13.6M – 195
2025
Q3 		$13.6M Buy
+346,001
New +$8.84M 1.37% 16
2020
Q3 		– Sell
-542
Closed -$65K – 190
2020
Q2 		$65K Buy
+542
New +$76.4K 0.01% 160
2020
Q1 		– Sell
-542
Closed -$131K – 160
2019
Q4 		$131K Buy
+542
New +$101K 0.02% 101

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital's DNTH Position: Q4 2025 in Review

Ikarian Capital sold out of Dianthus Therapeutics (DNTH) in Q4 2025, closing a stake of 346,001 shares — an estimated $13.6M sold.

Ikarian Capital first reported a position in DNTH in Q4 2019 and held it in 3 quarters. The position peaked at $13.6M in Q3 2025. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

  • Ikarian Capital reported no remaining Dianthus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 346,001 Dianthus Therapeutics shares in Q4 2025, an estimated $13.6M.
  • Ikarian Capital first reported a position in Dianthus Therapeutics in Q4 2019 and held it in 3 quarters.
  • Ikarian Capital's Dianthus Therapeutics position peaked at $13.6M in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.